FDA approves new blood test for Alzheimer’s disease

The U.S. Food and Drug Administration has approved Roche’s Elecsys Phospho‑Tau blood test for diagnosing Alzheimer’s disease, marking the fourth Alzheimer’s blood‑based diagnostic test cleared by the agency in under two years. The approval, announced by Roche on Sunday, adds to a rapidly expanding portfolio of laboratory tools that aim to detect the neurodegenerative condition through a simple blood draw rather than more invasive procedures such as lumbar puncture or costly imaging.

The Elecsys Phospho‑Tau assay measures phosphorylated tau protein, a biomarker associated with the formation of neurofibrillary tangles in the brain. FDA clearance follows a series of clinical studies that demonstrated the test’s ability to differentiate Alzheimer’s disease from other dementias with a high degree of accuracy. The move reflects the agency’s broader effort to facilitate earlier and more accessible diagnosis, potentially enabling timely therapeutic interventions and better patient management as the prevalence of Alzheimer’s continues to rise.